Product Description
AD-E6E7 is being developed by Turnstone Biologics for the treatment of patients with HPV-Associated Cancers. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT03618953?term=AD-E6E7&draw=2&rank=1)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Turnstone Biologics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Cervical Cancer|Oropharyngeal Cancer|Papilloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Kingfisher | P1 |
Terminated |
Papilloma|Oropharyngeal Cancer|Cervical Cancer |
2021-03-05 |
12% |
2023-04-15 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|